Bone Graft News and Research

RSS

50 U.S. Hospitals approve Osteotech's Plexur M bone-polymer biocomposite

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that Plexur M® (moldable), a bone-polymer biocomposite built upon the Company's proprietary Plexur® technology platform, has been approved for use by 50 U.S. hospitals to date. The Company expects to receive additional approvals as Plexur M continues to gain mindshare among surgeons.

1 Dec 2009

ApaTech named Europe's fastest growing company in Deloitte 2009 Technology Fast 500

ApaTech, the rapidly growing orthobiologics company, was named Europe's fastest growing Biotech/Pharmaceutical/Medical Technology/Equipment company in the Deloitte 2009 Technology Fast 500 for EMEA (Europe, Middle East and Africa).

30 Nov 2009

Minimally invasive procedure relieves chronic back pain for retired school teacher

Carole Riggs, a retired teacher and school principal, points to her work during one Christmas vacation - bending, twisting and sitting on the floor to create games and teaching aids - as the primary culprit behind many years of back pain.

24 Nov 2009

New, flexible scaffold for multi-level posterolateral fusion procedures

Medtronic, Inc. today announced the full U.S. market release of MASTERGRAFT® Strip – a new, highly flexible ceramic scaffold intended for use in combination with a patient’s own bone for fusing multiple levels of the posterolateral spine.

11 Nov 2009

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States

11 Nov 2009

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.

3 Nov 2009

First spinal surgery in the U.S. using Osteotech's MagniFuse PC bone graft technology performed

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that MagniFuse PC (Posterior Cervical) Bone Graft, a new tissue-based product built upon the Company's proprietary MagniFuse bone graft technology platform, has been used for the first time in a spinal surgery in the United States.

28 Oct 2009

Millennium Research Group to introduce bone morphogenetic proteins in South Korea

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.

27 Oct 2009

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Medtronic, Inc. today announced results of a study comparing the safety and effectiveness of INFUSE® Bone Graft to autogenous bone graft (bone harvested from the patient) when used in maxillary sinus floor augmentation.

14 Oct 2009

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

BioMimetic Therapeutics, Inc. today announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft for use in hindfoot and ankle fusion surgery.

14 Oct 2009

New study reports PRP treatment and its use in sports medicine

Platelet -rich plasma (PRP) is currently used as an alternative treatment method for several common orthopaedic-related sports medicine conditions.

3 Oct 2009

ETEX' Equivabone receives additional FDA clearance for use in posterolateral spine fusion

ETEX Corporation, an advanced biomaterials company, announced today additional FDA 510(k) cleared indications for EquivaBone®. EquivaBone was the first FDA cleared hard-setting osteoinductive material and is the only osteoinductive bone graft substitute that provides a continuous nanocrystalline calcium phosphate scaffold.

3 Oct 2009

FDA clearance for PRO-STIM bone graft substitute

Wright Medical Group, Inc., a global orthopaedic medical device company, today announced the 510K clearance of PRO-STIM™ Injectable Osteoinductive Bone Graft Substitute. PRO-STIM™ graft is a composite grafting material that is injected through a small needle, hardens, and is replaced by the patient’s new bone over time.

14 Sep 2009

$geneX combined with Mesenchymal stem cells for treating fracture$

geneX combined with Mesenchymal stem cells for treating fracture

Professor James B. Richardson of the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK has been carrying out pioneering work combining geneX with selected and culture expanded Mesenchymal stem cells to treat fracture non-unions.

7 Sep 2009

Recession impacts dental implant industry

Tooth loss among the elderly population will create some growth in the $3 billion global dental implant market despite the recession, according to "Implant-Based Dental Reconstruction: World Dental Implant and Bone Graft Market, 3rd Edition" by premier life sciences market research publisher Kalorama Information, though not the impressive double digit growth rates of prior years.

5 Sep 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

Biocomposites granted SFDA clearance for geneX in China

Biocomposites announced today that the company's unique bone graft substitute geneX , has been cleared for use by the State Food and Drug Administration (SFDA) of the People's Republic of China.

22 Feb 2009

Cellular grafting procedure helps young patients with knee disorder get active

At 14 years old, Adam Vasser of Los Altos, Calif., was an active kid who loved baseball.

2 Apr 2008

Greater use of spinal fusion has not lowered risk of repeat back surgery

Despite new implant technologies and surgical techniques leading to increased rates of spinal fusion surgery, the percentage of patients requiring further low-back surgery after spinal fusion has actually increased since the early 1990s, reports the Sept. 1 issue of the journal Spine, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

3 Sep 2007

Cervical disc to treat degenerative disease gets FDA green light

The Food and Drug Administration (FDA) in the U.S. has given approval for a cervical disc implant to treat patients with degenerative disc disease.

28 Aug 2007